Wertheim K, Chisholm R, Richmond P, Walker D
PLoS Comput Biol. 2024; 20(12):e1012648.
PMID: 39715281
PMC: 11723635.
DOI: 10.1371/journal.pcbi.1012648.
Zheng M, Kumar A, Sharma V, Behl T, Sehgal A, Wal P
Front Cell Dev Biol. 2024; 12:1353860.
PMID: 38601081
PMC: 11004261.
DOI: 10.3389/fcell.2024.1353860.
Shen J, Wang Q, Mao Y, Gao W, Duan S
MedComm (2020). 2023; 4(3):e288.
PMID: 37256211
PMC: 10225743.
DOI: 10.1002/mco2.288.
Blanco-Luquin I, Lazcoz P, Celay J, Castresana J, Encio I
Pharmaceuticals (Basel). 2021; 14(11).
PMID: 34832966
PMC: 8624165.
DOI: 10.3390/ph14111184.
Milan-Rois P, Quan A, Slack F, Somoza A
Cancers (Basel). 2021; 13(16).
PMID: 34439196
PMC: 8392202.
DOI: 10.3390/cancers13164041.
MYCN Function in Neuroblastoma Development.
Otte J, Dyberg C, Pepich A, Johnsen J
Front Oncol. 2021; 10:624079.
PMID: 33585251
PMC: 7873735.
DOI: 10.3389/fonc.2020.624079.
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
Zafar A, Wang W, Liu G, Xian W, McKeon F, Zhou J
Cancer Lett. 2020; 496:16-29.
PMID: 33007410
PMC: 8351219.
DOI: 10.1016/j.canlet.2020.09.023.
Transcriptome profiling reveals the role of ZBTB38 knock-down in human neuroblastoma.
Chen J, Xing C, Yan L, Wang Y, Wang H, Zhang Z
PeerJ. 2019; 7:e6352.
PMID: 30697495
PMC: 6348090.
DOI: 10.7717/peerj.6352.
Neuroblastoma treatment in the post-genomic era.
Esposito M, Aveic S, Seydel A, Tonini G
J Biomed Sci. 2017; 24(1):14.
PMID: 28178969
PMC: 5299732.
DOI: 10.1186/s12929-017-0319-y.
Anticancer Effects of the Marine Sponge sp. Extract on Wild-Type and p53 Knockout HCT116 Cells.
Choi K, Lim H, Oh S, Chung W, Jung J
Evid Based Complement Alternat Med. 2017; 2017:7174858.
PMID: 28127380
PMC: 5239977.
DOI: 10.1155/2017/7174858.
Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways.
Stepinski D
Histochem Cell Biol. 2016; 146(2):119-39.
PMID: 27142852
DOI: 10.1007/s00418-016-1443-6.
WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M, Dayaram T, Gilmartin A, Ganji G, Pemmasani S, Van Der Key H
PLoS One. 2015; 10(2):e0115635.
PMID: 25658463
PMC: 4319922.
DOI: 10.1371/journal.pone.0115635.
Neuroblastoma: molecular pathogenesis and therapy.
Louis C, Shohet J
Annu Rev Med. 2014; 66:49-63.
PMID: 25386934
PMC: 4418018.
DOI: 10.1146/annurev-med-011514-023121.
A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma.
Barbieri E, De Preter K, Capasso M, Johansson P, Man T, Chen Z
PLoS One. 2013; 8(11):e79843.
PMID: 24348903
PMC: 3865347.
DOI: 10.1371/journal.pone.0079843.
G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.
Hsu D, Agarwal S, Benham A, Coarfa C, Trahan D, Chen Z
Cancer Res. 2013; 73(13):4134-46.
PMID: 23687340
PMC: 4298227.
DOI: 10.1158/0008-5472.CAN-12-4056.
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.
Petroni M, Veschi V, Gulino A, Giannini G
Front Oncol. 2012; 2:141.
PMID: 23091802
PMC: 3470040.
DOI: 10.3389/fonc.2012.00141.
Pediatric oncology: G-CSF counteracts chemotherapy toxicity in neuroblastoma.
Russell H, Shohet J
Nat Rev Clin Oncol. 2010; 8(1):6-8.
PMID: 21102531
DOI: 10.1038/nrclinonc.2010.195.
